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Abstract:  
Objective:  Rett syndrome (RTT) is a severe neurodevelopmental disease that affects 
approximately 1 in 10,000 live female births and is often caused by mutations in Methyl-CpG-
binding protein 2 (MECP2).  Despite distinct clinical features, the accumulation of clinical and 
molecular information in recent years has generated considerable confusion regarding the 
diagnosis of RTT.  The purpose of this work was revise and clarify 2002 consensus criteria for the 
diagnosis of RTT in anticipation of treatment trials.  
 
Method:  RettBase members, representing the majority of the international clinical RTT specialists, 
participated in an iterative process to come to a consensus on a revised and simplified clinical 
diagnostic criteria for RTT. 
 
Results:  The clinical criteria required for the diagnosis of classic and atypical RTT were clarified 
and simplified.  Guidelines for the diagnosis and molecular evaluation of specific variant forms of 
RTT were developed. 
 
Interpretation: These revised criteria provide clarity regarding the key features required for the 
diagnosis of RTT and reinforce the concept that RTT is a clinical diagnosis based on distinct 
clinical criteria, independent of molecular findings.  We recommend that these criteria and 
guidelines be utilized in any proposed clinical research. 
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Note – this manuscript has been accepted by Annals of Neurology, and should be published online 
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Introduction 
Rett Syndrome (RTT, MIM 312750), an X-linked neurodevelopmental condition characterized by 
loss of spoken language and hand use with the development of distinctive hand stereotypies, was 
originally described in the 1960’s by Andreas Rett1.  In a seminal paper Bengt Hagberg and 
colleagues characterized the specific clinical features and initiated the eponym by which we 
recognize this clinical condition2.  The clinical diagnosis has been based on consensus clinical 
criteria3, which have been modified slightly over time to reflect increased understanding of the 
disease features, but have retained certain key clinical elements to make the diagnosis of classic, 
or typical, RTT.  In addition to typical RTT, it has been recognized that some individuals present 
with many of the clinical features of RTT, such as regression, but do not necessarily have all of the 
features of the disorder.  These have been termed "variant" or “atypical” RTT and have been found 
to cluster in some distinct clinical groupings, such as preserved speech variant, early seizure 
variant, and congenital variant4. 
 
In 1999, Amir and colleagues discovered that mutations in the gene encoding Methyl-CpG-binding 
protein 2 (MECP2) are associated both with rare familial cases of RTT as well as with the more 
common sporadic occurrences of typical RTT5.  Using a battery of modern mutation detection 
assays, mutations in MECP2 can be found in 95-97% of individuals with typical RTT6.  Importantly, 
even using the best methodologies, 3-5% of individuals who strictly meet clinical criteria for RTT do 
not have an identified mutation in MECP2, indicating that a mutation in this gene is not required to 
make the diagnosis of typical RTT6.  The situation is more dramatic in atypical cases, with only 50-
70% having identified mutations in MECP27. 
 
In addition to RTT, mutations in MECP2 have also been identified in individuals who do not have 
the clinical features of RTT.  At one end of the extreme are the asymptomatic female carriers found 
in familial RTT8.  The majority of these individuals have extreme skewing of their X chromosome 
inactivation (XCI), allowing a normal presentation.  At the opposite extreme are boys with MECP2 
mutations known to cause typical RTT in girls, but presenting with severe early postnatal 
encephalopathy, early death, and absence of the distinctive clinical features of RTT8, 9.  In addition 
to this early encephalopathy, rare individuals with mutations in MECP2 who present with other 
neurodevelopmental conditions such as autism10, Angelman syndrome-like presentation11, and 
non-specific intellectual disability have been described.  Although these individuals have some 
form of cognitive impairment, they lack features that define RTT, most importantly a history of 
regression, and therefore cannot be given a diagnosis of RTT.  These clinical phenotypes 
emphasize that mutations in MECP2 are not synonymous with RTT and that a mutation in MECP2 
is not sufficient to make the diagnosis of RTT.  Because MECP2 mutations are neither necessary 
nor sufficient to make the diagnosis of RTT, RTT remains a clinical diagnosis. 
 
Mutations in loci other than MECP2 have also been found in individuals that have been labeled as 
atypical RTT, although the criteria utilized have not always been clear.  For example, mutations in 
CDKL5 have been found in individuals with what has been characterized as early-seizure onset 
variant of RTT12,  However, the increasing identification of individuals with CDKL5 mutations has 
led to the observation that these individuals lack some of the distinctive clinical features of RTT 
such as the clear period of regression and the characteristic intense eye-gaze seen in individuals 
with typical RTT12.  Similarly, recent reports have identified mutations in FOXG1 in individuals 
characterized as having the congenital variant of RTT13, however it is not clear that applying a 
diagnosis of RTT is entirely appropriate because they do not have a clear history of regression. 
 
To address some of the confusion that currently exists regarding the diagnosis of RTT, the 
RettSearch Consortium participated in an iterative process to come to a consensus on revised and 
simplified diagnostic criteria for RTT.  RettSearch is an international network of clinically-oriented 
Rett syndrome researchers, composed of experts in RTT from thirteen different countries, which 
was initially established in 2006 through a meeting grant from the National Institutes of Health and 
additional support from the International Rett Syndrome Association (IRSA). Currently, it is 
supported by the International Rett Syndrome Foundation (IRSF), an organization which emerged 
in 2007 from the merge of IRSA and the Rett Syndrome Research Fund (RSRF).  RettSearch’s 
mission has been to promote the development of new therapeutic approaches for RTT by 
collecting information and pursuing collaborative research in areas of relevance to clinical trials in 
RTT. RettSearch has become the authoritative body regarding clinical matters in RTT and, in such 
capacity, it conducted the process of reviewing the diagnostic criteria for RTT. 
 
Revised clinical criteria for typical RTT 
The previous criteria of 2002 had eight necessary criteria, five exclusion criteria, and eight 
supportive criteria3.  The requirement for those criteria was never explicitly stated and one of the 
necessary criteria (postnatal deceleration of head growth in majority) was not absolutely required; 
furthermore, there was no requirement for any of the supportive criteria.  Observations such as 
these may be contributing to the diagnostic confusion we have noted. We developed revised 
diagnostic criteria (table 1) to clarify and simplify the diagnosis of typical, or classic, RTT.  We 
limited the necessary criteria to the presence of regression plus four main criteria that are 
absolutely required for the diagnosis of typical RTT.  The clinical picture associated with typical 
RTT is defined by a regression of purposeful hand use and spoken language, with the 
development of gait abnormalities and hand stereotypies.  After the period of regression, a stage of 
stabilization and potentially even improvement ensues, with some individuals partially regaining 
skills.  This potential for some skill recovery emphasizes the importance of the acquisition of a 
careful history to determine the presence of regression.  We eliminated post-natal deceleration in 
head growth from the necessary criteria because this feature in not found in all individuals with 
typical RTT14. However, because it is a clinical feature that can alert a clinician to the potential 
diagnosis and it is a distinctive feature in the disorder, we have included this as a preamble to the 
criteria as a feature that should raise suspicion for the diagnosis. 
 
The basic purpose of the exclusion criteria as written in the 2002 criteria was to exclude other 
potential causes of neurological disease, such as prematurity leading to intraventricular 
hemorrhage, or perinatal meningitis leading to diffuse brain damage.  We have thus streamlined 
this exclusion to a single statement that is meant to cover any other primary cause of neurological 
dysfunction.  There have been reports of individuals who have all the clinical features of typical 
RTT and disease-causing mutations in MECP2 but also have potential causes of neurological 
dysfunction, such as trisomy 2115.  These cases should not be classified as typical RTT because 
the diagnosis of typical RTT suggests a particular disease onset and course, which may be 
exacerbated by other confounding etiological entities.  Rather they should be considered an 
atypical form of RTT if they otherwise meet the consensus criteria (vide infra).   
 
The other exclusion criteria reflect the recognition that individuals with typical RTT do not have 
gross deviations in normal development in the first six months of life.  Although it has been 
recognized that some alterations in initial development can be present in these individuals16 
typically the family and the primary clinician is not concerned with development until after six 
months of life.  This is in contrast to one of the atypical forms of RTT, termed the congenital 
variant, in which development is grossly abnormal from birth.  Individuals who have such a 
developmental pattern should thus be evaluated using the atypical RTT criteria and given the 
diagnosis of atypical RTT-congenital form if they fulfill these criteria. 
 
The supportive criteria have been entirely eliminated from the diagnostic criteria for typical RTT 
because they are not required to make the diagnosis.  However, in recognition that many clinicians 
and importantly therapists and teachers sometimes suspect children as having RTT and refer them 
for detailed evaluation based on the presence of some key suggestive clinical features such as 
slowing in the rate of head growth, breathing abnormalities, and the intensive "Rett gaze" used for 
communication, they remain in the criteria for atypical RTT which are listed in the same table as 
the criteria for typical RTT (table 1).  In these new criteria, history of regression and ALL of the 
necessary and exclusion criteria MUST be met to make the diagnosis of typical RTT, without 
exception.  Of note, although initially recognized only in girls, boys who meet the criteria for typical 
RTT have been identified17 and thus should be considered to have typical RTT.  Recent work (See 
accompanying paper by Percy et al.) compared the diagnosis of a large cohort of individuals using 
the 2002 criteria with the diagnosis that will be applied to these same individuals using these 
revised criteria and found concordance between the two diagnostic criteria, validating that these 
revised criteria. 
 
Revised clinical criteria for atypical variants of RTT 
Although the 2002 report also put forth distinct criteria for assigning the diagnosis of variant RTT3, 
it is not clear that these guidelines have been followed precisely when making the diagnosis of 
variant, also known as atypical, RTT.  In the 2002 report, three of six main criteria were required for 
the diagnosis.  Inspection of the six main criteria reveals that four mention regression (absence or 
reduction of hand skills, reduction or loss of babble speech, reduction or loss of communication, 
Rett syndrome disease profile with a period of regression followed by recovery).  Thus, some form 
of regression is required for the diagnosis of atypical RTT.  The importance of regression for the 
diagnosis of RTT has long been recognized as demonstrated by a statement by Francoise 
Goutieres and Jean Aicardi in a paper from 1986 “The absence of normal initial development, 
followed by secondary deterioration and of loss of previously acquired voluntary hand grasp is 
especially important, as it is one of the essential traits of R(ett) S(yndrome)”18.  However, recent 
reports have diagnosed individuals with “atypical RTT” in the absence of any clear regression19.  
Many of the individuals in these reports have been found to have mutations in other loci and are 
increasingly recognized as having clinical features distinct from RTT13, 20, 21. which serves to 
emphasize the importance of regression in the diagnosis of RTT.  Therefore, in these revised 
criteria, in contrast to a recent report that did not emphasize regression in the diagnosis19, we state 
that for the diagnosis of atypical RTT an individual MUST have a period of regression followed by 
recovery or stabilization.  This clearly distinguishes these cases from relentless degenerative 
conditions.  In addition to having a regression, individuals must have at least two of the four main 
criteria and five of eleven supportive criteria. 
 
Specific variant forms of atypical RTT 
A variety of specifically defined variant forms of RTT have been recognized that have distinct 
clinical features.  Some of these forms have been recognized in only a small number of cases, 
making it difficult to make any clear statement concerning the defining clinical features.  However, 
multiple cases have been described for three distinct variant forms of RTT:  the preserved speech 
variant22, the congenital variant23, and the early seizure variant24.  The preserved speech variant is 
the best characterized, has well defined clinical features, and mutations in MECP2 have been 
found in the majority of cases25.  This is in contrast to both the congenital and the early seizure 
variant, in which mutations in MECP2 have only rarely been identified20, 21.  Recent work has found 
mutations in different loci associated with these variant forms, with mutations in CDKL5 found in 
early seizure variant cases12 and mutations in FOXG1 found in congenital variant cases13.  Figure 
1 shows the clinical features and the genetic loci associated with these specific variants of atypical 
RTT.  It should be noted that a diagnosis of one of these variants of RTT still requires the criteria 
stated above for atypical RTT to be meet.   
 
 
Characterization of individuals with RTT and/or with MECP2 mutations 
With the recognition that the presence of a MECP2 mutation is not sufficient for the diagnosis of 
RTT, the question remains of how to categorize and describe individuals with MECP2 mutations 
who do not have the clinical features of RTT.  We propose that all individuals with clinical disorders 
and MECP2 mutations be called MECP2-related disorders, which includes RTT and other 
neurological conditions associated with MECP2 mutations.  Those individuals with the clinical 
features required for the diagnosis of RTT should be referred to as having either typical or atypical 
RTT with mention of the genetic mutation identified.  For example, an individual might have typical 
RTT features with a disease causing mutation in MECP2.  This system would work for mutations in 
other loci.  For example, a clinical condition might be described as atypical RTT (early seizure 
variant) with a pathogenic mutation in CDKL5.   For those individuals without RTT, the underlying 
clinical condition should be referred to and then the presence of a MECP2 mutation mentioned.  
For example, those rare individuals with autism associated with a MECP2 mutation would be 
diagnosed as Autism with MECP2 mutation.  This nomenclature extends to individuals with 
duplications of the MECP2 locus who should be referred to by their clinical condition (i.e., autism, 
intellectually disabled, etc.) with a MECP2 duplication. 
 
Research study recommendations 
A variety of clinical trials in RTT are currently underway or imminent.  We feel it is important that 
clinical trials and other research studies utilize a basic set of guiding principles in regards to 
disease classification.  First, all individuals should be carefully assessed and classified clinically 
according to the revised clinical criteria.  The clinical diagnosis for all participants should be clearly 
stated in any publication.  Second, thorough and complete genetic testing for mutations in MECP2 
should be performed on all participants.  This would include sequencing of the coding region as 
well as methods such as MLPA, quantitative PCR, microarray methods, or Southern blotting to 
detect large DNA rearrangements.  Again, all genotype information should be provided in 
publications.  Because both clinical diagnosis and specific genetic mutations can modulate disease 
severity and associated clinical problems, we feel it is important that study design and data 
analysis account for these sources of variation.  These recommendations do not prohibit 
individuals with clinically definite typical RTT without a MECP2 mutation from participation, nor do 
they exclude those individuals with MECP2 mutations and a clinical condition distinct from RTT.  
Rather, these recommendations advise that analysis be performed in a manner to minimize clinical 
and genetic heterogeneity. 
 
Nomenclature recommendations 
Some have proposed the use of Rett Disorder to characterize individuals with Rett Syndrome who 
have mutations in MECP2.  This classification scheme creates confusion for the non-expert and 
should be avoided.  The term “Rett Syndrome, Typical” or “Rett Syndrome, Atypical” is preferred, 
with additional reference to the presence or absence of a MECP2 mutation.  There is variation in 
the abbreviation used for the clinical condition of Rett Syndrome.  We recommend the use of RTT 
and discourage the use of RS.  The rationale for this is firstly that this is the nomenclature given in 
Online Medelian Inheritence in Man - OMIM (http://www.ncbi.nlm.nih.gov/omim/), which has long 
been a standard reference for the nomenclature of genetic disorders; and secondly, the 
abbreviation RS can be confused with RS1, which is the accepted abbreviation for Retinoschisis 1, 
OMIM # 312700.   
 
Additional nomenclature issues 
Human gene: MECP2       (www.genenames.org/data/hgnc_data.php?hgnc_id=6990) 
Human protein: MeCP2    (www.uniprot.org/uniprot/P51608) 
Mouse gene: Mecp2 
Mouse protein: Mecp2 
MECP2_e1 = mRNA isoform that has its translational start site in exon 1 
MECP2_e2 = mRNA isoform that has its translational start site in exon 2 
Similarly, MECP2_e1 or MECP2_e2 for the protein isoform made from each mRNA isoform 
 
When naming specific sequence variations, it is important to use a standardized terminology. We 
recommend the following nomenclature: 
g. for genomic sequence (e.g., g.76A>T) 
c. for cDNA sequence (e.g., c.473C>T) 
p. for protein sequence (e.g., p.Thr158Met – avoid 1 letter codes) 
r. for RNA sequence (e.g., r.76a>u) 
m. for mitochondrial DNA sequence (e.g., m.8993T>C) 
 
For additional recommendations regarding how to identify specific sequence variations, refer to the 
Human Genome Variation Society’s website on Nomenclature for the description of sequence 
variations (http://www.hgvs.org/mutnomen/).  
 
RTT and MECP2 locus specific databases:  
1. RettBASE (http://mecp2.chw.edu.au/)  
2. EuroRETT (http://www.eurorett.eu/)  
3. InterRett (https://interrett.ichr.uwa.edu.au//?q=/rett/irsa/) 
4. Genetica Medica  (http://www.biobank.unisi.it/Elencorett.asp) 
5. MeCP2.org.uk (http://www.mecp2.org.uk/) 
 
 
 
Conclusions  
With the expansion of knowledge related to RTT and MECP2, reconsideration of diagnostic criteria 
for RTT and its variants and for other disorders that have been linked with RTT is warranted.  More 
than ten years after association of MECP2 mutations with RTT, the recommendations proposed 
above should clarify and refine clinical diagnoses and provide a framework for RTT-related 
conditions.  Strengths of these criteria are that they represent expert consensus opinion regarding 
the diagnosis and clinical categorization of RTT which have been validated using a large cohort of 
individuals with RTT (See accompanying paper by Percy et al.).  Beyond its utility in clinical 
management, the utilization of these criteria will ensure a high degree of homogeneity in 
populations enrolled in treatment trials and other clinical studies. One potential weakness of any 
revised criteria such as this is the possibility that some individuals may be inappropriately included 
or excluded from the diagnosis.  For this reason, the RettSearch community is commited to a 
process of continuous re-evaluation of these criteria, using the large clinical populations and 
datasets available to the membership, to ensure that the criteria are serving the stated purpose of 
providing a streamlined diagnostic framework that captures the clinical population of interest.  We 
recommend that these criteria and guidelines be utilized in any future clinical practice and 
research. 
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 RTT Diagnostic Criteria 2009 
 Consider diagnosis when postnatal deceleration of head growth observed. 
Required for typical or classic  RTT 
 1. A period of regression followed by recovery or stabilization* 
 2. All main criteria and all exclusion criteria 
 3. Supportive criteria are not required, although often present in typical RTT 
Required for atypical or variant  RTT 
  1. A period of regression followed by recovery or stabilization* 
  2. 2 out of main criteria  
  3. 5 out of 11 supportive criteria 
Main Criteria   
  1. Partial or complete loss of acquired purposeful hand skills. 
  2. Partial or complete loss of acquired spoken language** 
  3. Gait abnormalities:  Impaired (dyspraxic) or absence of ability. 
 
4. Stereotypic hand movements such as hand wringing/squeezing, clapping/tapping,  
mouthing and washing/rubbing automatisms 
Exclusion Criteria for typical RTT 
 
1. Brain injury secondary to trauma (peri- or postnatally), neurometabolic disease, or 
severe infection that causes neurological problems*** 
2. Grossly abnormal psychomotor development in first 6 months of life# 
Supportive Criteria for atypical RTT## 
  1. Breathing disturbances when awake 
  2. Bruxism when awake 
  3. Impaired sleep pattern 
  4. Abnormal muscle tone 
  5. Peripheral vasomotor disturbances 
  6. Scoliosis/kyphosis  
  7. Growth retardation 
  8. Small cold hands and feet 
  9. Inappropriate laughing/screaming spells 
 10. Diminished response to pain 
  11. Intense eye communication - “eye pointing” 
Table 1: Revised diagnostic criteria for RTT. 
* Because MECP2 mutations are now identified in some individuals prior to any clear evidence of 
regression, the diagnosis of "possible" RTT should be given to those individuals under 3 years old 
who have not lost any skills but otherwise have clinical features suggestive of RTT.  These 
individuals should be reassessed every 6-12 months for evidence of regression.  If regression 
manifests, the diagnosis should then be changed to definite RTT.  However, if the child does not 
show any evidence of regression by 5 years, the diagnosis of RTT should be questioned. 
** Loss of acquired language is based on best acquired spoken language skill, not strictly on the 
acquisition of distinct words or higher language skills. Thus, an individual who had learned to 
babble but then loses this ability is considered to have a loss of acquired language. 
***There should be clear evidence (neurological or ophthalmological examination and MRI/CT) that 
the presumed insult directly resulted in neurological dysfunction. 
# Grossly abnormal to the point that normal milestones (acquiring head control, swallowing, 
developing social smile) are not met.  Mild generalized hypotonia or other previously reported 
subtle developmental alterations16  during the first six months of life is common in RTT and do not 
constitute an exclusionary criterion. 
## If an individual has or ever had a clinical feature listed it is counted as a supportive criterion.  
Many of these features have an age dependency, manifesting and becoming more predominant at 
certain ages.  Therefore, the diagnosis of atypical RTT may be easier for older individuals than for 
younger.  In the case of a younger individual (under 5 years old) who has a period of regression 
and >2 main criteria but does not fulfill the requirement of 5/11 supportive criteria, the diagnosis of 
"probably atypical RTT" may be given.  Individuals who fall into this category should be reassessed 
as they age and the diagnosis revised accordingly.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Variant forms of RTT 
•Meets criteria for atypical RTT 
•Assess for presence of clinical features of defined variant forms 
Preserved Speech Variant 
 (Zappella Variant) 
Clinical features 
•Regression at 1-3 yrs, prolonged plateau 
phase 
•Milder reduction of hand skills 
•better retained hand use 
•Recovery of language after regression  
•Mean age of recovery is 5 yrs 
•Single words or phrases 
•Milder intellectual disability (IQ up to 50) 
•Autistic behaviors common 
•Decreased frequency of typical RTT 
features 
•Rare epilepsy 
•Rare autonomic dysfunction 
•Milder scoliosis and kyphosis 
•Normal head circumference 
•Normal height and weight in 
most 
Molecular Genetics 
Mutations in MECP2 found in the 
majority of cases 
Early Seizure Variant 
 (Hanefeld Variant) 
Clinical features 
•Early onset of seizures 
•Before 5 months of life 
•Infantile spasms 
•Refractory myoclonic epilepsy 
•Seizure onset before 
regression 
•Decreased frequency of typical RTT 
features 
•Limited or no head growth 
deceleration 
•No somatic growth failure 
•No or limited autonomic 
dysfunction 
•Absence of intense “RTT” eye 
gaze  
Molecular Genetics 
Mutations in MECP2 rarely found 
Analysis for mutations in CDKL5 
 should be performed 
Congenital Variant 
 (Rolando Variant) 
Clinical features 
•Grossly abnormal initial development 
•Severe psychomotor delay 
•Inability to walk 
•Severe postnatal microcephaly before 4 
months 
•Regression in first 5 months 
•Lack of typical intense “RTT” eye gaze 
•Typical RTT autonomic abnormalities 
present 
•Small cold hands and feet 
•Peripheral vasomotor 
disturbances 
•Breathing abnormalities while 
awake 
•Specific movement abnormalities 
•Tongue stereotypies 
•Jerky movements of the limbs 
Molecular Genetics 
Mutations in MECP2 rarely found 
Analysis for mutations in      
 FOXG1should be performed 
 Figure 1: Specific variant forms of RTT flow diagram 
